Chitosan nanoparticles as a drug delivery system

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 1, Issue 3, 2010, Pages 474-484

  Krishna Sailaja, A ^a   Amareshwar, P ^a   Chakravarty, P ^a  

^a OSMANIA UNIVERSITY   (India)

Author keywords

Drug delivery carriers; Nanoparticles; Polymers

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; CHITIN; CHITOSAN; DOXORUBICIN; IMMUNOGLOBULIN A; NANOPARTICLE; OPSONIN; POLYELECTROLYTE; POLYETHYLENEIMINE; POLYLYSINE; SIALIC ACID;

CANCER INHIBITION; CHEMICAL STRUCTURE; DEACETYLATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; EMULSION; ENZYME DEGRADATION; GELATION; GENE TRANSFER; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MICROEMULSION; MOLECULAR WEIGHT; MUCOADHESION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PEYER PATCH; PHYSICAL CHEMISTRY; RETICULOENDOTHELIAL SYSTEM; REVIEW; TIGHT JUNCTION;

EID: 79952522168     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Illum, L. Pharm. Res 1998;15:1326-1331.
2. Kreuter, J. Nanoparticles. In: Colloidal Drug Delivery Systems, edited by Kreuter, J. New York: Marcel Dekker, 1994; 261-276.
3. Mueller, R. H. Colloidal Carriers for Controlled Drug Delivery and Targeting, Boston: CRC Press, 1991,379 p.
4. Hoppe-Seiler F. Ber Dtsch Chem Ges. 1994; 27:3329-3331.
5. Roberts GAF. Solubility and solution behaviour of chitin and chitosan. In: Roberts GAF, ed. Chitin Chemistry. MacMillan, Houndmills. 1992:274-329.
6. Muzzarelli RAA, Baidassare V, Conti F, Gazzanelli G, Vasi V, Ferrara P, Biagini G Biomaterials 1988;8:247-252.
7. Miyazaki S, Ishii K, Nadai T. Chem Pharm Bull 1981;29:3067-3069.
8. Kurita K. Chemical modifications of chitin and chitosan. In: Muzzarelli RAA, Jeuniaux C, Gooday GW, eds. Chitin in Nature and Technology. Plenum: New York, NY. 1986:287-293.
9. Roberts GAF. Structure of chitin and chitosan.ln:Roberts GAF,ed,Chitin chemistry.Mac Millan, Houndmills. 1992: 1-53.
10. Allemann, ER Gurny and E Doelker. Eur J Pharm Biopharm 1993;39: 173-191.
11. Janes KA, MP Fresneau, A Marazuela, A Fabra and MJ Alonso. J Control Release 2001; 73:255-267.
12. Gerlowski LE and RK Jain. Microvasc Res 1986;31: 288-305.
13. Bender ARH, Von Briesen J, Kreuter IB, Duncan and H Rubsamen-Waigmann. Antimicrob Agents Chemother 1996;40: 1467 1471.
14. Luessen HL, BJ de Leeuw, MW Langemeyer AB. de Boer, JC Verhoef and HE Junginger. Pharm Res 1996; 13:1668-1672.
15. Norris GN, Puri and PJ Sinko. Adv Drug Deliv Rev 1998; 34: 135-154.
16. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. Int J Pharm 1992;78:43-48.
17. Fernandez-Urrusuno RP, Calvo C, Remunan-Lopez, JL Vila-Jato and MJ Alonso. Pharm Res 1999; 16:1576-1581.
18. Dyer AM, M Hinchcliffe P, Watts J, Castile I, Jabbal-Gill, R Nankervis, A Smith, and L Illum. Pharm Res 2002;19:998-1008.
19. Erbacher P, S Zou, AM Steffan, and JS Remy. Pharm Res 1998; 15:1332-1339.
20. Guang Liu W and K De Yao. J Control Release 2002; Vol. 83, pp. 1-11.
21. Lemkine GF and BA Demeneix. Curr Opin Mol Ther 2001; 3: 178-182.
22. Hirano S. Biotechnol Annu Rev 1996;2:237-258.
23. De Campos AMA, Sanchez and MJ Alonso. Int J Pharm 2001 224:159-168.
24. Felt O, P Furrer, JM, Mayer B, Plazonnet P, Buri and R Gurny. Int J Pharm. 1999;180:185-193.
25. lonso MJ, Sanchez A. J Pharm Pharmacol 2003;55:1451-1463.
26. Illum LI, Jabbal-Gill, M Hinchcliffe, AN Fisher, and SS Davis. Adv Drug Deliv Rev 2001;51:81-96.
27. Kreuter J, Chapter 19: Nanoparticles as adjuvants for vaccines. ln:Vaccine Design, edited by Powell MF, and MJ Newman. New York: Plenum Press, 1995;463-471.
28. Van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. Vaccine. 2003;28:1400-1408.